Humanized antibodies have become the mainstay of therapeutic antibody development and still represent the majority of antibody-based clinical candidates and marketed therapeutic antibodies. A number of competing technologies for humanizing antibodies have emerged in the last 20 years, but it is the original, CDR grafting technique which is responsible for the vast majority of humanised antibodies on the market and in the clinic.
DaTaMabs is the antibody engineering consultancy which provides the efficient and proven technology solution for your antibody humanization program.
We provide a complete design service enabling you successfully to apply the antibody humanization technology which is directly responsible for the majority of therapeutic antibodies on the world market.
Our partnership is able to draw on over 25 years of antibody humanization-focused know-how. Our expertise is responsible for the successful humanization of nearly 40 humanized antibodies.
